Pharvaris N.V. (PHVS) vs Arcus Biosciences (RCUS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Pharvaris N.V. (PHVS) has outperformed Arcus Biosciences (RCUS) over the past year, gaining 26.0% versus a loss of 29.2%. Over five years, PHVS leads with a +131.3% price change compared with -66.3% for RCUS. Arcus Biosciences is the larger company by market cap ($2.25 billion vs $2.21 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PHVS | RCUS |
|---|---|---|
| Share price | $31.28 | $15.62 |
| Market cap | $2.21B | $2.25B |
| 1-day change | -1.20% | -1.01% |
| YTD return | +12.72% | -34.45% |
| 1-year return | +25.98% | -29.16% |
| 5-year return | +131.28% | -66.31% |
| EPS (TTM) | $-3.13 | $-3.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $247.00M |
| Revenue growth (YoY) | — | -4.26% |
| Net income (latest FY) | $-25.99M | $-353.00M |
| Operating margin | — | -156.28% |
| Net margin | — | -142.91% |
| 52-week high | $43.25 | $31.74 |
| 52-week low | $23.15 | $15.56 |
| Distance from 52-week high | -27.68% | -50.78% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +86.29% | +162.48% |
| Average volume | 756.20K | 1.85M |
| Shares outstanding | 70.79M | 143.99M |
| Employees | 168 | 601 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PHVS has outperformed RCUS by 55.1 percentage points over the past year.
About Pharvaris N.V.
PHVS stock →Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant.
Health Care · Biotechnology: Pharmaceutical Preparations · 168 employees
About Arcus Biosciences
RCUS stock →Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody.
Health Care · Biotechnology: Pharmaceutical Preparations · 601 employees
PHVS vs RCUS FAQ
Which is bigger, Pharvaris N.V. or Arcus Biosciences?
Arcus Biosciences (RCUS) is larger, with a market capitalization of $2.25B compared with $2.21B for Pharvaris N.V. (PHVS).
Which stock has performed better over the past year, PHVS or RCUS?
PHVS returned +25.98% over the past 12 months, compared with -29.16% for RCUS (price return, excluding dividends). Past performance does not predict future results.
Are Pharvaris N.V. and Arcus Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.